News
SRPT
16.19
+1.06%
0.17
Weekly Report: what happened at SRPT last week (0615-0619)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC)
TipRanks · 4d ago
Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Simply Wall St · 5d ago
Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators?
Simply Wall St · 6d ago
Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly Stance
Seeking Alpha · 06/18 13:48
Analysts Offer Insights on Healthcare Companies: Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT)
TipRanks · 06/18 11:41
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
Benzinga · 06/17 17:33
Weekly Report: what happened at SRPT last week (0608-0612)?
Weekly Report · 06/15 09:04
Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?
Simply Wall St · 06/08 09:15
Weekly Report: what happened at SRPT last week (0601-0605)?
Weekly Report · 06/08 09:04
A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering
Simply Wall St · 06/06 01:17
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
TipRanks · 06/04 21:32
Sarepta Therapeutics shareholders approve 2026 equity incentive plan at annual meeting
PUBT · 06/04 20:31
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 06/04 18:16
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
TipRanks · 06/04 16:34
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 06/01 15:30
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Reuters · 06/01 12:31
Weekly Report: what happened at SRPT last week (0525-0529)?
Weekly Report · 06/01 09:04
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.